- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
In response to hypoxia, tumor cells often produce multiple proangiogenic growth factors. These can bind to and activate different receptor tyrosine kinases. The activation of Fibroblast Growth Factor Receptor (FGFR), Platelet-derived Growth Factor Receptor (PDGFR) or Vascular Endothelial Growth Factor Receptor (VEGFR) leads to the promotion of angiogenesis.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
